Product | MedDrive®


Leveraging the collective strength of Prime’s client membership to help control medical costs including biosimilars, medical rebates and low net cost savings.

Related news

Press releases

May 26, 2021

Prime Therapeutics launches MedDrive™, a first-of-its kind medical drug management program uniquely aligned with its Blue Plan clients

MedDrive to tackle the toughest challenges facing growing medical Rx drug spend, harness the multi-billion-dollar potential savings in biosimilar market

Press releases

November 3, 2021

Prime Therapeutics backs first interchangeable insulin biosimilar Semglee®

Formularies to include biosimilar over brand Lantus®, saving millions of dollars for health plans and their members


September 8, 2021

Prime leaders appear on PCMA’s podcast on topic “Understanding the value of biosimilars”

Prime’s Dr. Joseph Leach and Jarrod Henshaw discuss the opportunity, how the company’s new MedDrive™ medical drug management product will help manage growing specialty spend